HOME > Business Wire > Article
Transition of Promotional Activities for Allergen Immunotherapy Drug Actair® in Japan
BAAR, Switzerland & OSAKA, Japan & TOKYO--( BUSINESS WIRE )-- Stallergenes Greer, Shionogi & Co., Ltd. (“Shionogi”) and CEOLIA Pharma Co. Ltd (“CEOLIA”) today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702309702/en/
After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair® in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair®. Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance.
Stallergenes Greer acknowledges Shionogi’s contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies.
ABOUT STALLERGENES GREER
Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries.
For more information, visit www.stallergenesgreer.com.
ABOUT SHIONOGI & Co. Ltd
Shionogi has identified “Contributing to a Healthy and Prosperous Life” as one of its key material issues. The group is committed to building a society where everyone can live vibrantly and true to themselves. With a continued focus on areas of high unmet medical needs, Shionogi strives to deliver innovative treatments that improve the quality of life (QOL) for patients and their families.
For more information, visit https://www.shionogi.com/jp/ja/
ABOUT CEOLIA
CEOLIA, founded in 2010, is a pharmaceutical company dedicated to serving all healthcare needs in the otolaryngology (ENT) field. With a mission and philosophy to serve and contribute to people's health and happiness, we develop and manufacture and market ethical drugs, medical devices, and diagnostic reagents in the ENT field. For more information, visit https://www.ceolia.co.jp/.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250702309702/en/
Contacts
Stallergenes Greer
Communications
Catherine Kress
Tel: +33 (0)1 55 50 26 05
Email:
catherine.kress@stallergenesgreer.com
Shionogi
SHIONOGI Website Inquiry Form:
www.shionogi.com/global/en/contact
CEOLIA
Tel: +81 3 3243 1135
CEOLIA Website enquiry form:
www.ceolia.co.jp/en/contact/enquiry_form
Source: Stallergenes Greer
Business Wire
-
07/03 06:30 Transition of Promotional Activities for Allergen Immunotherapy Drug A...
-
07/03 04:18 KIOXIA AiSAQ™ Software Advances AI RAG with New Version of Vector Se...
-
07/03 03:01 NIPPON KINZOKU: Welded Drawn Pipe Surpassing Seamless Pipes; Introduci...
-
07/02 15:12 JCR Pharmaceuticals Announces the Achievement of Enrollment in the JR-...
-
07/02 12:30 Asahi Kasei Pharma Starts Phase III Study of Promising CIPN Prevention...
-
07/02 08:11 AN Venture Partners Announces Final Close of $200M Fund I
-
07/02 02:00 Pacifica Hotels to Open the First IHG Garner brand in Kyoto, Japan
-
07/02 00:00 Access Advance Welcomes Global Technology Leaders as Licensees and Lic...
-
07/01 15:30 Renesas Strengthens Power Leadership with New GaN FETs for High-Densit...
-
07/01 15:30 Renesas Sets New MCU Performance Bar with 1-GHz RA8P1 Devices with AI ...
-
07/01 12:00 Tailor Expands Series A to $22M with Private-Public Support
-
07/01 12:00 FELIQS announces $9 Million Series A Financing to Advance FLQ-101 Clin...
-
07/01 06:00 1Finity, a Fujitsu Company, Commences Operations and Reveals Brand Ide...
-
07/01 05:00 PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform i...
-
06/30 22:00 NTT Solmare to Exhibit Obey Me! and Ex and Bee at Anime Expo 2025!
-
06/30 13:03 Bubbies Ice Cream Acquired by Marubeni Corporation
-
06/30 12:05 NTT Wins Fast Company World Changing Ideas Award for Project Humanity
-
06/30 12:00 Spirent and Juniper Networks Collaborate to Showcase First Public UET ...
-
06/30 12:00 Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only R...
-
06/30 07:00 Endo Tools Therapeutics and Fujifilm Middle East FZE Partner to Extend...
-
06/30 07:00 RevolKa Ltd. Joins Research and Development Program for Innovative Bio...
-
06/30 06:00 Logo Established for the “Japan Creator Support Fund” to Support t...
-
06/30 02:00 Marumatsu Reimagines Everyday Tea Culture with Renewed "san grams Sang...
-
06/27 23:30 SBC Medical added to membership of Russell 3000® Index
-
06/27 14:00 Ubitus and NMNS Launch AI-Powered Virtual Guide to Explore the World o...
-
06/27 14:00 PRD Therapeutics Announces Initiation of First-in-Human Study for PRD001
-
06/27 09:09 Nidec Announces Approval of Deadline Extension for Submission of the S...
-
06/27 07:00 Gigaphoton Triples its Field Service Capacity in Kyushu
-
06/26 16:57 A New Chapter Begins: Cross Management Corporation Joins Forces with G...
-
06/26 14:00 Rigaku Expands Production Facilities for the Semiconductor Market